Abstract
Histone deacetylases 6 (HDAC6) has emerged as a promising target for the treatment of various human diseases including cancer, neurodegenerative disease and immunology due to its unique structure, substrate and biological functions. HDAC6 is involved in cell motility, cell survival, cell cycle progression, developmental events, prognosis as well as protein degradation and the involvement of HDAC6 in multiple biological processes has gained lots of attention. There is increasing interest in HDAC6 and its selective inhibitors. More than twenty years of synthetic efforts have developed various HDAC6 selective inhibitors with different Cap, linker and ZBG. This review will summarize recent research data regarding HDAC6 and various HDAC6 selective inhibitors.
Keywords: Epigenetics, HDAC6, Protein degradation, Neurodegenerative disease, Cancer, HDAC6 selective inhibitors.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Structure, Functions and Selective Inhibitors of HDAC6
Volume: 18 Issue: 28
Author(s): Tao Liang and Hao Fang*
Affiliation:
- Department of Medicinal Chemistry, Key Laboratory of Chemical Biology, School of Pharmaceutical Sciences, Shandong University, 44, Wenhuaxi Road, Jinan, Shandong, 250012,China
Keywords: Epigenetics, HDAC6, Protein degradation, Neurodegenerative disease, Cancer, HDAC6 selective inhibitors.
Abstract: Histone deacetylases 6 (HDAC6) has emerged as a promising target for the treatment of various human diseases including cancer, neurodegenerative disease and immunology due to its unique structure, substrate and biological functions. HDAC6 is involved in cell motility, cell survival, cell cycle progression, developmental events, prognosis as well as protein degradation and the involvement of HDAC6 in multiple biological processes has gained lots of attention. There is increasing interest in HDAC6 and its selective inhibitors. More than twenty years of synthetic efforts have developed various HDAC6 selective inhibitors with different Cap, linker and ZBG. This review will summarize recent research data regarding HDAC6 and various HDAC6 selective inhibitors.
Export Options
About this article
Cite this article as:
Liang Tao and Fang Hao *, Structure, Functions and Selective Inhibitors of HDAC6, Current Topics in Medicinal Chemistry 2018; 18 (28) . https://dx.doi.org/10.2174/1568026619666181129141822
DOI https://dx.doi.org/10.2174/1568026619666181129141822 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting FLT3 Kinase in Acute Myelogenous Leukemia: Progress, Perils, and Prospects
Mini-Reviews in Medicinal Chemistry Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present)
Recent Patents on Anti-Cancer Drug Discovery Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications
Current Cancer Drug Targets Long Noncoding RNA OIP5-AS1 Overexpression Promotes Viability and Inhibits High Glucose-Induced Oxidative Stress of Cardiomyocytes by Targeting MicroRNA-34a/SIRT1 Axis in Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Anticancer Chemodiversity of Ranunculaceae Medicinal Plants: Molecular Mechanisms and Functions
Current Genomics Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Dietary Polyphenols for Prostate Cancer Therapy
Current Bioactive Compounds From Target Therapy to miRNA Therapeutics of Human Multiple Myeloma: Theoretical and Technological Issues in the Evolving Scenario
Current Drug Targets 17 AAG for HSP90 Inhibition in Cancer – From Bench to Bedside
Current Molecular Medicine CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets Role of Unani Medicines in Cancer Control and Management
Current Drug Therapy Selected Players in the Inflammation Cascade and Drugs That Target These Inflammation Genes Against Metastasis
Anti-Cancer Agents in Medicinal Chemistry E-Cadherin Upregulation as a Therapeutic Goal in Cancer Treatment
Mini-Reviews in Medicinal Chemistry Endocrine Therapy of Breast Cancer
Current Medicinal Chemistry Thalidomide Chemotherapy-Induced Peripheral Neuropathy: Actual Status and New Perspectives with Thalidomide Analogues Derivatives
Mini-Reviews in Medicinal Chemistry Peptide Vaccines for Cancer Therapy
Recent Patents on Inflammation & Allergy Drug Discovery Therapeutic microRNA Delivery Strategies with Special Emphasis on Cancer Therapy and Tumorigenesis: Current Trends and Future Challenges
Current Drug Metabolism A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma
Current Medicinal Chemistry Targeting CXCR4 in HIV Cell-Entry Inhibition.
Mini-Reviews in Medicinal Chemistry